Expression of STATs and their inhibitors SOCS and PIAS in brain tumors. in vitro and in vivo study

Neoplasma

Volumn 55, Issue 6, 2008, Pages 482-487

  Ehrmann, J ^a   Strakova, N ^a   Vrzalikova, K ^a   Hezova, R ^a   Kolar, Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Brain tumors; PIAS; PPARs; SOCS; STAT

Indexed keywords

CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 3; STAT2 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHAPERONE; PIAS1 PROTEIN, HUMAN; PIAS3 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT PROTEIN; SUMO PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; ASTROCYTOMA; CELL VIABILITY; CONTROLLED STUDY; EPENDYMOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; BRAIN TUMOR; DRUG ANTAGONISM; GENE EXPRESSION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MOLECULAR CHAPERONES; PHOSPHORYLATION; PPAR GAMMA; PROTEIN INHIBITORS OF ACTIVATED STAT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; STAT TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION;

EID: 59749101577     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. RAWLINGS JS, ROSLER KM, HARRISON DA. The JAK/ STAT signaling pathway. J Cell Sci 2004; 117: 1281-1283.
2. IMADA K, LEONARD WJ. The Jak - STAT pathway. Mol Immunol 2000; 37: 1-11.
3. STEPHANOU A, LATCHMAN DS. STAT-1: a novel regulator of apoptosis. Intl J Exp Pathol 2004; 84: 239-244.
4. DARNELL JE, Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
5. TANIGUCHI T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995; 268: 251-255.
6. PARGANAS E, WANG D, STRAVOPODIS D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 397-409.
7. O'SHEA JJ, GADINA M, SCHREIBER RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109: Suppl. S121-S131.
8. STARR R, WILLSON TA, VINEY EM et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917-921.
9. SHUAI K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000; 19: 2638-2644. (Pubitemid 30339220)
10. NEEL BG, TONKS NK. Protein tyrosine phosphatases in signal transduction. Current Opin Cell Biol 199; 9: 193-204.
11. WORMALD S, HILTON DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004; 279: 821-824.
12. LIU B. Inhibition of STAT1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998; 95: 10626-10631.
13. FRANK DA. STAT signaling in the pathogenesis and treatment of cancer. Mol Med 1999; 5: 432-456. (Pubitemid 29399750)
14. BOWMAN T, GARCIA R, TURKSON J et al. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
15. CHENG F. A critical role for STAT3 signaling in immune tolerance. Immunity 2003; 19: 425-436. (Pubitemid 37153418)
16. WANG T, NIU G, KORTYLEWSKI M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med 2004; 10: 48-54. (Pubitemid 38524698)
17. MANNS MP, MCHUTCHISON JG, GORDON SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
18. YU H, JOVE R. The Stats of cancer - new molecular targets come of age. Nature Rev Cancer 2004; 4: 97-105.
19. BROMBERG J. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-1142.
20. WANG L, BANERJEE S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004; 11: 1319-1324.
21. BOUDNÝ V, KOVARIK J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 2002; 49: 349-355.
22. CARAGLIA M. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 2005; 202: 323-335. (Pubitemid 40041303)
23. SUN WH, PABON C, ALSAYED Y et al. Interferon alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998; 91: 570-576.
24. CHIARLE R, SIMMONS WJ, CAI H et al. Stat 3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Med 2005; 11: 623-629.
25. WARD AC, TOUW I, YOSHIMURA A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000; 95: 19-29.
26. GOUILLEUX-GRUART V, GOUILLEUX F, DESAINT C et al. Stat-related transcription factors are constitutively activated in peripheral blood cells from acute leukaemia patients. Blood 1996; 87: 1692-1697.
27. KOVARIK J, BOUDNY V, KOCAK I et al. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 2003; 12: 335-434
28. BOUDNÝ V, KOCÁK I, LAUEROVÁ L et al. Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol 2003; 49: 142-146.
29. GRANDIS J, DRENNING SD, ZENG Q et al. Constitutive activation of STAT3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-4232
30. FERNANDES A, HAMBURGER AW, GERWIN BI. ErbB-2 kinase is required for constitutive STAT3 activation in malignant human lung epithelial cells. Int J Cancer 1999; 83: 564-570.
31. CLEVENGER CV. Roles and regulation of Stat family transcription factors in human breast cancer. Am J Pathol 2004; 165: 1449-1460.
32. OSTRAND-ROSENBERG S, GRUSBY MJ, CLEMENTS VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 2000; 165: 6015-6019.
33. WATSON CJ. Stat transcription factors in mammary gland development. J Mammary Gland Biol and Neoplasia 2001; 6: 115-127.
34. DARNELL JE, Jr. Validating Stat3 in cancer therapy. Nature Med 2005; 11: 595-596.
35. TURKSON J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409-422. (Pubitemid 39359648)
36. BUETTNER R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002; 8: 945-954.
37. KIM HJ, RHO YH, CHOI SJ et al. 15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced STAT3 phosphorylation in lymphocytes. Exp Mol Med 2005; 3: 179-185.
38. PARK EJ, PARK SY, JOE EH et al. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 2003; 17: 14747-14752
39. LEE JH, JOE EH, JOU I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. Neuroreport 2005; 8: 829-833.
40. STRAKOVA N, EHRMANN J, BARTOS J et al. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma. 2005; 52: 126-136. (Pubitemid 40503415)
41. STRAKOVA N, EHRMANN J, DZUBAK P et al. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 2004; 309: 1239-1247
42. CATTANEO E, MAGRASSI L, DE-FRAJA C et al. Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res 1998; 18: 2381-2387
43. SCHAEFER LK, REN Z, FULLER FN et al. Constitutive activation of STAT3 alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002; 21: 2058-2065.
44. YAO Y, KUBOTA T, SATO K et al. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional and mRNA stabilization in human glioblastoma cells. Journal of Neuro-Oncology 2005; 72: 217-223.
45. RAJASINGH J, BRIGHT JJ. 15-deoxy-delta12, 14-prostaglandin J2 regulates leukemia inhibitory factor signaling through JAK-STAT pathway in mouse embryonic stem cells. Exp Cell Res 2006; 312: 2538-2546
46. KINO T, RICE KC, CHROUSOS GP. The PPAR delta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 2007; 37: 425-433.
47. FERRAJOLI A, FADERL S, RAVANDI F et al. The JAKSTAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006; 6: 671-679 (Pubitemid 44875961)
48. PARK EJ, PARK SY, JOE EH et al. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 2003; 278: 14747-14752
49. SALLINEN SL, SALLINEN P, AHLSTEDT-SOINI M et al. Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. Cancer Gen Cytogen 2003; 144: 52-60.
50. CORAS R, HÖLSKEN A, SEUFERT S et al. The peroxisome proliferator-activated receptor-gama agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 2007; 6: 1745-1754